Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
166
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
629
mi
from 43215
Minneapolis, MN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
629
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
HealthEast St. Joseph's Hospital
617
mi
from 43215
Saint Paul, MN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
HealthEast St. Joseph's Hospital
617
mi
from 43215
Saint Paul, MN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
St. Luke's Hospital of Kansas City
619
mi
from 43215
Kansas City, MO
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
St. Luke's Hospital of Kansas City
619
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Cox Medical Centers
588
mi
from 43215
Springfield, MO
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Cox Medical Centers
588
mi
from 43215
Springfield, MO
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
609
mi
from 43215
Lebanon, NH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
609
mi
from 43215
Lebanon, NH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Deborah Heart and Lung Center
446
mi
from 43215
Browns Mills, NJ
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Deborah Heart and Lung Center
446
mi
from 43215
Browns Mills, NJ
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Morristown Memorial Hospital
453
mi
from 43215
Morristown, NJ
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Morristown Memorial Hospital
453
mi
from 43215
Morristown, NJ
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Presbyterian Hospital
1333
mi
from 43215
Albuquerque, NM
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Presbyterian Hospital
1333
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital
493
mi
from 43215
Manhasset, NY
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital
493
mi
from 43215
Manhasset, NY
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
New York Univ. Medical Center
477
mi
from 43215
New York, NY
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
New York Univ. Medical Center
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital Health Center
415
mi
from 43215
Syracuse, NY
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital Health Center
415
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center
349
mi
from 43215
Charlotte, NC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center
349
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Wake Medical Center
377
mi
from 43215
Raleigh, NC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Wake Medical Center
377
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital
98
mi
from 43215
Cincinnati, OH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
0
mi
from 43215
Columbus, OH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
0
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
OhioHealth Research and Innovation Institute - Riverside Methodist Hospital
4
mi
from 43215
Columbus, OH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
OhioHealth Research and Innovation Institute - Riverside Methodist Hospital
4
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Mercy St. Vincent Medical Center
119
mi
from 43215
Toledo, OH
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Mercy St. Vincent Medical Center
119
mi
from 43215
Toledo, OH
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Integris Baptist Medical Center
849
mi
from 43215
Oklahoma City, OK
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Integris Baptist Medical Center
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Oklahoma Heart Hospital
848
mi
from 43215
Oklahoma City, OK
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Oklahoma Heart Hospital
848
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Providence St. Vincent Medical Center
2031
mi
from 43215
Portland, OR
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Providence St. Vincent Medical Center
2031
mi
from 43215
Portland, OR
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center
344
mi
from 43215
Danville, PA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center
344
mi
from 43215
Danville, PA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
165
mi
from 43215
Pittsburgh, PA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
165
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Lankenau Medical Center
410
mi
from 43215
Wynnewood, PA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Lankenau Medical Center
410
mi
from 43215
Wynnewood, PA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Sisters of Charity Providence Hospital
425
mi
from 43215
Columbia, SC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Sisters of Charity Providence Hospital
425
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
University Medical Center-Greenville Memorial Hospital
355
mi
from 43215
Greenville, SC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
University Medical Center-Greenville Memorial Hospital
355
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Grand Strand Regional Medical Center
487
mi
from 43215
Myrtle Beach, SC
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Grand Strand Regional Medical Center
487
mi
from 43215
Myrtle Beach, SC
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Jackson Madison County General Hospital
431
mi
from 43215
Jackson, TN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Jackson Madison County General Hospital
431
mi
from 43215
Jackson, TN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Centennial Medical Center
333
mi
from 43215
Nashville, TN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Centennial Medical Center
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Baylor Heart and Vascular Hospital
910
mi
from 43215
Dallas, TX
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Baylor Heart and Vascular Hospital
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
St. Luke's Episcopal Hospital
995
mi
from 43215
Houston, TX
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
St. Luke's Episcopal Hospital
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
The Heart Hospital Baylor Plano
901
mi
from 43215
Plano, TX
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
The Heart Hospital Baylor Plano
901
mi
from 43215
Plano, TX
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
St. David's Round Rock Medical Center
1052
mi
from 43215
Round Rock, TX
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
St. David's Round Rock Medical Center
1052
mi
from 43215
Round Rock, TX
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
University of Vermont Medical Center
591
mi
from 43215
Burlington, VT
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
University of Vermont Medical Center
591
mi
from 43215
Burlington, VT
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Sentara Norfolk General Hospital
422
mi
from 43215
Norfolk, VA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Sentara Norfolk General Hospital
422
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
2005
mi
from 43215
Seattle, WA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Charleston Area Medical Center
137
mi
from 43215
Charleston, WV
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Charleston Area Medical Center
137
mi
from 43215
Charleston, WV
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Aurora St. Luke's Medical Center
329
mi
from 43215
Milwaukee, WI
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Aurora St. Luke's Medical Center
329
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Instituto do Coração (InCor)
4974
mi
from 43215
Sao Paulo,
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Instituto do Coração (InCor)
4974
mi
from 43215
Sao Paulo,
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Northwestern Memorial Hospital
274
mi
from 43215
Chicago, IL
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Northwestern Memorial Hospital
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Northern Indiana Research Alliance - Lutheran Hospital
136
mi
from 43215
Fort Wayne, IN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Northern Indiana Research Alliance - Lutheran Hospital
136
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Winchester Medical Center
264
mi
from 43215
Winchester, VA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Winchester Medical Center
264
mi
from 43215
Winchester, VA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
El Camino Hospital
2097
mi
from 43215
Mountain View, CA
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
El Camino Hospital
2097
mi
from 43215
Mountain View, CA
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Carle Foundation Hospital
274
mi
from 43215
Urbana, IL
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Carle Foundation Hospital
274
mi
from 43215
Urbana, IL
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
MedStar Washington Hospital Center
328
mi
from 43215
Washington,
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
MedStar Washington Hospital Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated:  12/31/1969
Baptist Memorial Hospital
502
mi
from 43215
Memphis, TN
EVOLVE Short DAPT Study
A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
Status: Enrolling
Updated: 12/31/1969
Baptist Memorial Hospital
502
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
Click here to add this to my saved trials